JFG
NTLA icon

Jefferies Financial Group’s Intellia Therapeutics NTLA Stock Holding History

Jefferies Financial Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.8K Buy
3,000
+2,000
+200% +$28K ﹤0.01% 1574
2026
Q1 		$12.8K Buy
+1,000
New +$12.7K ﹤0.01% 1683
2024
Q3 		– Sell
-700
Closed -$15.7K – 1662
2024
Q2 		$15.7K Buy
+700
New +$16.7K ﹤0.01% 1351

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Jefferies Financial Group's NTLA Position: Q2 2026 in Review

Jefferies Financial Group increased its Intellia Therapeutics (NTLA) stake by 200% in Q2 2026, buying an estimated $28K and bringing the position to 3,000 shares worth $50.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1574.

Jefferies Financial Group first reported a position in NTLA in Q2 2024 and has held it in 3 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Jefferies Financial Group held 3,000 shares of Intellia Therapeutics worth $50.8K as of Q2 2026.
  • Jefferies Financial Group bought 2,000 Intellia Therapeutics shares in Q2 2026, an estimated $28K.
  • Intellia Therapeutics made up ﹤0.01% of Jefferies Financial Group's portfolio in Q2 2026, its #1574 holding.
  • Jefferies Financial Group first reported a position in Intellia Therapeutics in Q2 2024 and has held it in 3 quarters since.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.